Literature DB >> 1411086

Cyclosporin A in a pregnant patient affected with systemic lupus erythematosus.

A Doria1, L Di Lenardo, S Vario, A Calligaro, E Vaccaro, P F Gambari.   

Abstract

Few data regarding the use of cyclosporin A (CyA) in pregnancy are available and those available refer mainly to transplant recipients and not to patients with connective tissue diseases. We report the case of a patient with systemic lupus erythematosus (SLE), taking CyA before, during and after her pregnancy at a dose of 4 mg/kg per day. CyA was effective in controlling SLE activity and no side effects were observed in mother or baby. The lack of teratogenicity in this case was in keeping with previous reports in experimental systems, animals and human transplant recipients. If our observation is confirmed by further studies, CyA might become useful in the treatment of pregnant patients with SLE.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1411086     DOI: 10.1007/bf00300981

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  10 in total

1.  Patterns of MHC antigenic modulation in cyclosporine-induced autoimmunity. Implications for pathogenesis.

Authors:  N A Parfrey; G J Prud'homme
Journal:  Am J Pathol       Date:  1990-02       Impact factor: 4.307

2.  Psoriasis, cyclosporine, and pregnancy.

Authors:  S Wright; M Glover; H Baker
Journal:  Arch Dermatol       Date:  1991-03

Review 3.  Effects of antiinflammatory and immunosuppressive drugs on pregnancy and fertility.

Authors:  R Roubenoff; J Hoyt; M Petri; M C Hochberg; D B Hellmann
Journal:  Semin Arthritis Rheum       Date:  1988-11       Impact factor: 5.532

4.  Organ-specific autoimmune disease induced in mice by elimination of T cell subsets. V. Neonatal administration of cyclosporin A causes autoimmune disease.

Authors:  S Sakaguchi; N Sakaguchi
Journal:  J Immunol       Date:  1989-01-15       Impact factor: 5.422

5.  Present experience of Sandimmun in pregnancy.

Authors:  I Cockburn; P Krupp; C Monka
Journal:  Transplant Proc       Date:  1989-08       Impact factor: 1.066

6.  The place of cyclosporine A in the treatment of connective tissue diseases.

Authors:  P A Miescher; H Favre; M J Mihatsch; F Chatelanat; Y P Huang; R Zubler
Journal:  Transplant Proc       Date:  1988-06       Impact factor: 1.066

7.  Absence of genotoxic potential for cyclosporine in experimental systems.

Authors:  T S Zwanenburg; W Suter; B E Matter
Journal:  Transplant Proc       Date:  1988-06       Impact factor: 1.066

Review 8.  Lupus pregnancy.

Authors:  M D Lockshin
Journal:  Clin Rheum Dis       Date:  1985-12

9.  Cyclosporin A in patients receiving renal allografts from cadaver donors.

Authors:  R Y Calne; D J White; S Thiru; D B Evans; P McMaster; D C Dunn; G N Craddock; B D Pentlow; K Rolles
Journal:  Lancet       Date:  1978 Dec 23-30       Impact factor: 79.321

Review 10.  Toxicological evaluation of cyclosporin A.

Authors:  B Ryffel; P Donatsch; M Madörin; B E Matter; G Rüttimann; H Schön; R Stoll; J Wilson
Journal:  Arch Toxicol       Date:  1983-06       Impact factor: 5.153

  10 in total
  3 in total

Review 1.  Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options?

Authors:  M Ostensen; R Ramsey-Goldman
Journal:  Drug Saf       Date:  1998-11       Impact factor: 5.606

Review 2.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 3.  Ciclosporin use during pregnancy.

Authors:  Karolina Paziana; Magaly Del Monaco; Elyce Cardonick; Michael Moritz; Matthew Keller; Bruce Smith; Lisa Coscia; Vincent Armenti
Journal:  Drug Saf       Date:  2013-05       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.